| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.989 | 0.001 | 0.989 | Factor XII inhibitor | |||
| 0.981 | 0.003 | 0.981 | Apoptosis agonist | |||
| 0.864 | 0.002 | 0.864 | Amyloid beta precursor protein antagonist | |||
| 0.756 | 0.005 | 0.756 | Thioredoxin glutathione reductase inhibitor | |||
| 0.653 | 0.003 | 0.653 | Chelator | |||
| 0.644 | 0.003 | 0.644 | Growth hormone agonist | |||
| 0.582 | 0.004 | 0.619 | Alpha-N-acetylglucosaminidase inhibitor | 0.619 0.004 DBMET00531 | DBMET00531 | |
| 0.584 | 0.009 | 0.592 | GABA C receptor rho-3 antagonist | 0.592 0.008 DBMET00531 | DBMET00531 | |
| 0.523 | 0.003 | 0.523 | Tyk2 inhibitor | |||
| 0.529 | 0.029 | 0.535 | Aldehyde oxidase inhibitor | 0.535 0.028 DBMET00531 | DBMET00531 | |
| 0.515 | 0.027 | 0.515 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.514 0.028 DBMET00531 | ||
| 0.489 | 0.002 | 0.489 | EphA2 antagonist | |||
| 0.509 | 0.026 | 0.509 | 5 Hydroxytryptamine release stimulant | 0.49 0.029 DBMET00531 | ||
| 0.484 | 0.001 | 0.484 | Thioredoxin inhibitor | |||
| 0.481 | 0.001 | 0.481 | HCV polyprotein inhibitor | |||
| 0.436 | 0.004 | 0.497 | GABA C receptor agonist | 0.497 0.004 DBMET00531 | DBMET00531 | |
| 0.441 | 0.015 | 0.456 | Peroxidase inhibitor | 0.456 0.014 DBMET00531 | DBMET00531 | |
| 0.435 | 0.014 | 0.435 | Calcium channel activator | 0.355 0.046 DBMET00531 | ||
| 0.427 | 0.023 | 0.427 | DNA damaging | |||
| 0.442 | 0.055 | 0.464 | 5 Hydroxytryptamine release inhibitor | 0.464 0.046 DBMET00531 | DBMET00531 | |
| 0.395 | 0.015 | 0.402 | 5 Hydroxytryptamine uptake stimulant | 0.402 0.014 DBMET00531 | DBMET00531 | |
| 0.381 | 0.009 | 0.381 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.243 0.046 DBMET00531 | ||
| 0.374 | 0.003 | 0.374 | MAP kinase kinase 5 inhibitor | |||
| 0.434 | 0.063 | 0.434 | Antibacterial | |||
| 0.37 | 0.003 | 0.37 | Nociceptin (N/OFQ) receptor antagonist | |||
| 0.38 | 0.02 | 0.38 | RNA-directed DNA polymerase inhibitor | 0.268 0.041 DBMET00531 | ||
| 0.362 | 0.002 | 0.362 | Neuraminidase (influenza) inhibitor | |||
| 0.361 | 0.004 | 0.378 | Ferrochelatase inhibitor | 0.378 0.004 DBMET00531 | DBMET00531 | |
| 0.367 | 0.013 | 0.372 | Tyrosine 3 hydroxylase inhibitor | 0.372 0.012 DBMET00531 | DBMET00531 | |
| 0.366 | 0.021 | 0.366 | Anesthetic general | 0.227 0.061 DBMET00531 | ||
| 0.384 | 0.042 | 0.384 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | |||
| 0.347 | 0.005 | 0.347 | Carbonic anhydrase XV inhibitor | 0.134 0.038 DBMET00531 | ||
| 0.408 | 0.071 | 0.408 | 15-Lipoxygenase inhibitor | |||
| 0.332 | 0.007 | 0.332 | Ephrin antagonist | |||
| 0.322 | 0.002 | 0.322 | Ca(v)3.1 blocker | |||
| 0.418 | 0.101 | 0.429 | Caspase 9 stimulant | 0.429 0.095 DBMET00531 | DBMET00531 | |
| 0.331 | 0.034 | 0.331 | DNA synthesis inhibitor | 0.26 0.06 DBMET00531 | ||
| 0.296 | 0.005 | 0.296 | Mannose-6-phosphate isomerase inhibitor | 0.199 0.031 DBMET00531 | ||
| 0.329 | 0.041 | 0.342 | Superoxide dismutase inhibitor | 0.342 0.038 DBMET00531 | DBMET00531 | |
| 0.306 | 0.018 | 0.306 | Cytidine deaminase inhibitor | |||
| 0.293 | 0.011 | 0.309 | UDP-glucose 4-epimerase inhibitor | 0.309 0.01 DBMET00531 | DBMET00531 | |
| 0.313 | 0.042 | 0.313 | Interleukin agonist | 0.262 0.07 DBMET00531 | ||
| 0.275 | 0.006 | 0.275 | Analgesic, opioid | |||
| 0.281 | 0.014 | 0.303 | Succinate dehydrogenase inhibitor | 0.303 0.01 DBMET00531 | DBMET00531 | |
| 0.267 | 0.003 | 0.267 | Neuraminidase inhibitor | |||
| 0.271 | 0.009 | 0.271 | 5 Hydroxytryptamine 3E antagonist | 0.262 0.012 DBMET00531 | ||
| 0.264 | 0.009 | 0.264 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | |||
| 0.353 | 0.099 | 0.37 | Histamine release inhibitor | 0.37 0.09 DBMET00531 | DBMET00531 | |
| 0.259 | 0.008 | 0.259 | Carbonic anhydrase VI inhibitor | 0.084 0.052 DBMET00531 | ||
| 0.249 | 0.002 | 0.249 | Nociceptin (N/OFQ) receptor agonist | |||
| 0.251 | 0.01 | 0.257 | Adenylate kinase inhibitor | 0.257 0.009 DBMET00531 | DBMET00531 | |
| 0.264 | 0.024 | 0.279 | Nitric-oxide synthase stimulant | 0.279 0.018 DBMET00531 | DBMET00531 | |
| 0.242 | 0.007 | 0.274 | Triose-phosphate isomerase inhibitor | 0.274 0.005 DBMET00531 | DBMET00531 | |
| 0.242 | 0.008 | 0.263 | Porphobilinogen synthase inhibitor | 0.263 0.007 DBMET00531 | DBMET00531 | |
| 0.238 | 0.01 | 0.238 | Carbonic anhydrase XIII inhibitor | 0.07 0.058 DBMET00531 | ||
| 0.233 | 0.005 | 0.233 | Electrolyte absorption antagonist | 0.156 0.017 DBMET00531 | ||
| 0.246 | 0.019 | 0.525 | Aldehyde dehydrogenase inhibitor | 0.525 0.004 DBMET00531 | DBMET00531 | |
| 0.24 | 0.014 | 0.253 | GABA C receptor rho-2 antagonist | 0.253 0.011 DBMET00531 | DBMET00531 | |
| 0.234 | 0.008 | 0.234 | NADH dehydrogenase inhibitor | 0.229 0.009 DBMET00531 | ||
| 0.318 | 0.094 | 0.318 | Prostaglandin dehydrogenase inhibitor | |||
| 0.227 | 0.005 | 0.915 | Alcohol oxidase inhibitor | 0.915 0.002 DBMET00531 | DBMET00531 | |
| 0.228 | 0.012 | 0.248 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.248 0.01 DBMET00531 | DBMET00531 | |
| 0.219 | 0.01 | 0.235 | GABA C receptor antagonist | 0.235 0.008 DBMET00531 | DBMET00531 | |
| 0.211 | 0.005 | 0.211 | Janus tyrosine kinase 1 inhibitor | |||
| 0.201 | 0.002 | 0.201 | Exportin-1 inhibitor | 0.103 0.008 DBMET00531 | ||
| 0.202 | 0.005 | 0.202 | Carbonic anhydrase VB inhibitor | 0.062 0.033 DBMET00531 | ||
| 0.29 | 0.097 | 0.303 | Cholesterol antagonist | 0.303 0.089 DBMET00531 | DBMET00531 | |
| 0.27 | 0.08 | 0.274 | Insulysin inhibitor | 0.274 0.076 DBMET00531 | DBMET00531 | |
| 0.197 | 0.011 | 0.2 | Creatine kinase inhibitor | 0.2 0.01 DBMET00531 | DBMET00531 | |
| 0.285 | 0.1 | 0.285 | Vasodilator, coronary | 0.249 0.136 DBMET00531 | ||
| 0.191 | 0.008 | 0.196 | Carbamoyl phosphate synthetase inhibitor | 0.196 0.008 DBMET00531 | DBMET00531 | |
| 0.191 | 0.009 | 0.205 | GABA C receptor rho-1 antagonist | 0.205 0.007 DBMET00531 | DBMET00531 | |
| 0.185 | 0.005 | 0.187 | Ca2+-transporting ATPase inhibitor | 0.187 0.005 DBMET00531 | DBMET00531 | |
| 0.254 | 0.074 | 0.254 | Gastrin inhibitor | 0.253 0.076 DBMET00531 | ||
| 0.266 | 0.087 | 0.266 | Hypoxia-inducible factor 1 alpha inhibitor | |||
| 0.206 | 0.027 | 0.212 | Arachidonic acid antagonist | 0.212 0.023 DBMET00531 | DBMET00531 | |
| 0.195 | 0.017 | 0.195 | 5 Hydroxytryptamine 3A agonist | 0.187 0.019 DBMET00531 | ||
| 0.311 | 0.133 | 0.311 | Analgesic | |||
| 0.19 | 0.012 | 0.205 | Phosphofructokinase-1 inhibitor | 0.205 0.011 DBMET00531 | DBMET00531 | |
| 0.179 | 0.007 | 0.19 | Biliverdin reductase inhibitor | 0.19 0.006 DBMET00531 | DBMET00531 | |
| 0.212 | 0.04 | 0.212 | Amylase inhibitor | 0.16 0.059 DBMET00531 | ||
| 0.174 | 0.002 | 0.174 | Calcium-dependent phospholipase A2 inhibitor | |||
| 0.178 | 0.007 | 0.181 | Acyl-CoA dehydrogenase inhibitor | 0.181 0.006 DBMET00531 | DBMET00531 | |
| 0.179 | 0.009 | 0.179 | Carbonic anhydrase V inhibitor | 0.06 0.054 DBMET00531 | ||
| 0.195 | 0.026 | 0.208 | Cystathionine beta-synthase inhibitor | 0.208 0.023 DBMET00531 | DBMET00531 | |
| 0.245 | 0.08 | 0.245 | 5 Hydroxytryptamine 1E antagonist | 0.238 0.088 DBMET00531 | ||
| 0.181 | 0.025 | 0.185 | Adenylate cyclase stimulant | 0.185 0.022 DBMET00531 | DBMET00531 | |
| 0.163 | 0.009 | 0.163 | Carbonic anhydrase VA inhibitor | 0.066 0.051 DBMET00531 | ||
| 0.18 | 0.028 | 0.18 | Nav1.6 sodium channel blocker | 0.124 0.089 DBMET00531 | ||
| 0.186 | 0.036 | 0.186 | Cell wall synthesis inhibitor | 0.139 0.076 DBMET00531 | ||
| 0.163 | 0.014 | 0.176 | Glutamate dehydrogenase inhibitor | 0.176 0.012 DBMET00531 | DBMET00531 | |
| 0.212 | 0.066 | 0.216 | Neurotrophic factor enhancer | 0.216 0.062 DBMET00531 | DBMET00531 | |
| 0.245 | 0.103 | 0.245 | Lipoxygenase inhibitor | |||
| 0.157 | 0.017 | 0.157 | Janus tyrosine kinase 3 inhibitor | |||
| 0.145 | 0.009 | 0.145 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.142 0.009 DBMET00531 | ||
| 0.155 | 0.019 | 0.166 | DOPA decarboxylase inhibitor | 0.166 0.015 DBMET00531 | DBMET00531 | |
| 0.14 | 0.009 | 0.14 | Protein kinase C eta inhibitor | |||
| 0.152 | 0.021 | 0.152 | Prolactin inhibitor | 0.145 0.024 DBMET00531 | ||
| 0.135 | 0.004 | 0.135 | Phospholipase D inhibitor | 0.099 0.015 DBMET00531 | ||
| 0.133 | 0.003 | 0.133 | AMPA receptor agonist | |||
| 0.144 | 0.014 | 0.165 | Glutamate decarboxylase inhibitor | 0.165 0.011 DBMET00531 | DBMET00531 | |
| 0.162 | 0.033 | 0.171 | Aminopeptidase B inhibitor | 0.171 0.03 DBMET00531 | DBMET00531 | |
| 0.139 | 0.013 | 0.157 | Argininosuccinate synthase inhibitor | 0.157 0.011 DBMET00531 | DBMET00531 | |
| 0.171 | 0.046 | 0.174 | CF transmembrane conductance regulator agonist | 0.174 0.043 DBMET00531 | DBMET00531 | |
| 0.145 | 0.021 | 0.145 | Telomerase inhibitor | |||
| 0.151 | 0.031 | 0.151 | Protein kinase C gamma inhibitor | |||
| 0.193 | 0.073 | 0.193 | DNA methyltransferase I inhibitor | |||
| 0.158 | 0.042 | 0.158 | Cyclooxygenase 3 inhibitor | 0.143 0.055 DBMET00531 | ||
| 0.135 | 0.022 | 0.16 | Histidine decarboxylase inhibitor | 0.16 0.018 DBMET00531 | DBMET00531 | |
| 0.177 | 0.065 | 0.18 | Phospholipase C inhibitor | 0.18 0.061 DBMET00531 | DBMET00531 | |
| 0.128 | 0.016 | 0.141 | Phenylalanine 4-hydroxylase inhibitor | 0.141 0.013 DBMET00531 | DBMET00531 | |
| 0.118 | 0.006 | 0.144 | Aconitate hydratase inhibitor | 0.144 0.004 DBMET00531 | DBMET00531 | |
| 0.124 | 0.013 | 0.132 | Granulocyte macrophage colony stimulating factor agonist | 0.132 0.01 DBMET00531 | DBMET00531 | |
| 0.128 | 0.017 | 0.131 | Aminopeptidase I inhibitor | 0.131 0.016 DBMET00531 | DBMET00531 | |
| 0.178 | 0.067 | 0.189 | 3C-like protease (Human coronavirus) inhibitor | 0.189 0.059 DBMET00531 | DBMET00531 | |
| 0.144 | 0.035 | 0.144 | Nav1.1 sodium channel blocker | |||
| 0.158 | 0.05 | 0.158 | Sphingosine 1-phosphate receptor 5 antagonist | 0.157 0.05 DBMET00531 | ||
| 0.135 | 0.027 | 0.141 | Anabolic | 0.141 0.023 DBMET00531 | DBMET00531 | |
| 0.191 | 0.085 | 0.191 | DNA methylase inhibitor | |||
| 0.134 | 0.03 | 0.35 | Catalase inhibitor | 0.35 0.005 DBMET00531 | DBMET00531 | |
| 0.15 | 0.046 | 0.156 | Cathepsin H inhibitor | 0.156 0.042 DBMET00531 | DBMET00531 | |
| 0.165 | 0.061 | 0.171 | Interferon gamma antagonist | 0.171 0.056 DBMET00531 | DBMET00531 | |
| 0.123 | 0.02 | 0.124 | Glutamate release inhibitor | 0.124 0.019 DBMET00531 | DBMET00531 | |
| 0.113 | 0.011 | 0.113 | NMDA receptor glycine site agonist | 0.08 0.028 DBMET00531 | ||
| 0.167 | 0.066 | 0.167 | Neurotensin receptor agonist | 0.167 0.067 DBMET00531 | ||
| 0.115 | 0.014 | 0.115 | NMDA receptor agonist | 0.074 0.033 DBMET00531 | ||
| 0.149 | 0.049 | 0.149 | Heat shock protein 70 antagonist | 0.149 0.049 DBMET00531 | ||
| 0.131 | 0.033 | 0.139 | HIV-1 integrase (Overall Integration) inhibitor | 0.139 0.03 DBMET00531 | DBMET00531 | |
| 0.117 | 0.02 | 0.118 | Glycine receptor antagonist | 0.118 0.019 DBMET00531 | DBMET00531 | |
| 0.102 | 0.006 | 0.102 | Corticotropin releasing factor 2 receptor antagonist | 0.067 0.032 DBMET00531 | ||
| 0.145 | 0.049 | 0.145 | Alkylator | |||
| 0.104 | 0.009 | 0.104 | Glutamate (mGluR7) antagonist | 0.104 0.009 DBMET00531 | ||
| 0.111 | 0.015 | 0.114 | Glycine receptor agonist | 0.114 0.014 DBMET00531 | DBMET00531 | |
| 0.123 | 0.028 | 0.123 | Lanosterol 14 alpha demethylase inhibitor | 0.119 0.032 DBMET00531 | ||
| 0.1 | 0.005 | 0.111 | Glucose-6-phosphate isomerase inhibitor | 0.111 0.004 DBMET00531 | DBMET00531 | |
| 0.13 | 0.034 | 0.13 | Acetylcholine release stimulant | 0.129 0.036 DBMET00531 | ||
| 0.162 | 0.067 | 0.162 | Diuretic | |||
| 0.27 | 0.176 | 0.27 | Alpha-glucosidase inhibitor | |||
| 0.136 | 0.041 | 0.141 | Photosensitizer | 0.141 0.037 DBMET00531 | DBMET00531 | |
| 0.107 | 0.014 | 0.11 | Purinergic P2X1 antagonist | 0.11 0.014 DBMET00531 | DBMET00531 | |
| 0.121 | 0.029 | 0.121 | Histamine N-methyltransferase inhibitor | 0.112 0.035 DBMET00531 | ||
| 0.143 | 0.051 | 0.143 | Sphingosine 1-phosphate receptor 2 antagonist | 0.143 0.05 DBMET00531 | ||
| 0.108 | 0.017 | 0.108 | Estrogen-related receptor beta agonist | 0.108 0.017 DBMET00531 | ||
| 0.12 | 0.03 | 0.121 | Glutamate (mGluR7) agonist | 0.121 0.03 DBMET00531 | DBMET00531 | |
| 0.135 | 0.048 | 0.135 | Calcium channel N-type blocker | |||
| 0.231 | 0.143 | 0.231 | Vasodilator, peripheral | 0.226 0.148 DBMET00531 | ||
| 0.1 | 0.013 | 0.101 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.101 0.013 DBMET00531 | DBMET00531 | |
| 0.102 | 0.015 | 0.102 | 5 Hydroxytryptamine 3 agonist | 0.069 0.037 DBMET00531 | ||
| 0.134 | 0.047 | 0.134 | Microtubule formation inhibitor | 0.127 0.053 DBMET00531 | ||
| 0.098 | 0.011 | 0.107 | Glutamate (mGluR6) antagonist | 0.107 0.008 DBMET00531 | DBMET00531 | |
| 0.097 | 0.012 | 0.097 | Carbonic anhydrase XIV inhibitor | |||
| 0.145 | 0.062 | 0.145 | Pregnane X receptor agonist | 0.142 0.069 DBMET00531 | ||
| 0.087 | 0.004 | 0.087 | Dopamine beta hydroxylase inhibitor | 0.059 0.017 DBMET00531 | ||
| 0.099 | 0.018 | 0.101 | Vanilloid 4 agonist | 0.101 0.016 DBMET00531 | DBMET00531 | |
| 0.095 | 0.014 | 0.095 | Opioid agonist | |||
| 0.122 | 0.043 | 0.122 | Urease inhibitor | 0.088 0.081 DBMET00531 | ||
| 0.158 | 0.079 | 0.158 | Heat shock protein 90 alpha antagonist | |||
| 0.093 | 0.014 | 0.093 | Heat shock protein 90 beta antagonist | |||
| 0.115 | 0.036 | 0.115 | Protein kinase C zeta inhibitor | |||
| 0.104 | 0.025 | 0.108 | D-Ala-D-Ala ligase inhibitor | 0.108 0.021 DBMET00531 | DBMET00531 | |
| 0.14 | 0.063 | 0.14 | Nav1.2 sodium channel blocker | |||
| 0.239 | 0.162 | 0.239 | Beta lactamase inhibitor | |||
| 0.097 | 0.022 | 0.097 | Acetylcholine M5 receptor agonist | 0.094 0.023 DBMET00531 | ||
| 0.087 | 0.011 | 0.087 | Carbonic anhydrase VII inhibitor | |||
| 0.125 | 0.05 | 0.132 | Mucolytic | 0.132 0.045 DBMET00531 | DBMET00531 | |
| 0.092 | 0.018 | 0.101 | Ornithine carbamoyltransferase inhibitor | 0.101 0.016 DBMET00531 | DBMET00531 | |
| 0.107 | 0.033 | 0.111 | CYP2A6 inhibitor | 0.111 0.031 DBMET00531 | DBMET00531 | |
| 0.098 | 0.024 | 0.098 | CC chemokine 5 receptor agonist | 0.095 0.028 DBMET00531 | ||
| 0.125 | 0.052 | 0.125 | GABA receptor agonist | |||
| 0.091 | 0.018 | 0.091 | Protein kinase C beta inhibitor | |||
| 0.104 | 0.031 | 0.104 | Myeloperoxidase inhibitor | |||
| 0.151 | 0.078 | 0.151 | Cyclin-dependent kinase 8 inhibitor | |||
| 0.123 | 0.051 | 0.126 | Falcipain 3 inhibitor | 0.126 0.05 DBMET00531 | DBMET00531 | |
| 0.092 | 0.021 | 0.092 | MAP kinase kinase 7 inhibitor | 0.09 0.024 DBMET00531 | ||
| 0.102 | 0.031 | 0.102 | mTOR complex 2 inhibitor | 0.098 0.035 DBMET00531 | ||
| 0.076 | 0.008 | 0.086 | Fumarate hydratase inhibitor | 0.086 0.006 DBMET00531 | DBMET00531 | |
| 0.079 | 0.012 | 0.079 | Alpha-mannosidase inhibitor | 0.077 0.012 DBMET00531 | ||
| 0.099 | 0.033 | 0.1 | Na+ K+ transporting ATPase inhibitor | 0.1 0.031 DBMET00531 | DBMET00531 | |
| 0.132 | 0.066 | 0.14 | Toll-Like receptor 2 antagonist | 0.14 0.059 DBMET00531 | DBMET00531 | |
| 0.082 | 0.016 | 0.082 | Potassium channel intermediate-conductance Ca-activated blocker | 0.066 0.031 DBMET00531 | ||
| 0.082 | 0.017 | 0.082 | MDM2 inhibitor | 0.069 0.041 DBMET00531 | ||
| 0.072 | 0.008 | 0.072 | Dopamine D5 agonist | 0.071 0.008 DBMET00531 | ||
| 0.111 | 0.048 | 0.113 | Sphingomyelinase inhibitor | 0.113 0.047 DBMET00531 | DBMET00531 | |
| 0.068 | 0.006 | 0.068 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.047 0.01 DBMET00531 | ||
| 0.095 | 0.033 | 0.095 | Interferon agonist | 0.081 0.051 DBMET00531 | ||
| 0.123 | 0.062 | 0.124 | Cholesterol synthesis inhibitor | 0.124 0.061 DBMET00531 | DBMET00531 | |
| 0.069 | 0.008 | 0.069 | Alpha 1d adrenoreceptor agonist | 0.062 0.01 DBMET00531 | ||
| 0.193 | 0.132 | 0.193 | Neuropeptide Y2 antagonist | 0.191 0.137 DBMET00531 | ||
| 0.072 | 0.011 | 0.078 | Adenylate cyclase 1 inhibitor | 0.078 0.009 DBMET00531 | DBMET00531 | |
| 0.147 | 0.086 | 0.154 | Melanin inhibitor | 0.154 0.076 DBMET00531 | DBMET00531 | |
| 0.088 | 0.028 | 0.094 | GABA B receptor agonist | 0.094 0.022 DBMET00531 | DBMET00531 | |
| 0.154 | 0.095 | 0.159 | ATPase inhibitor | 0.159 0.087 DBMET00531 | DBMET00531 | |
| 0.071 | 0.013 | 0.073 | Pregnane X receptor antagonist | 0.073 0.011 DBMET00531 | DBMET00531 | |
| 0.065 | 0.008 | 0.065 | Guanylate cyclase inhibitor | 0.064 0.008 DBMET00531 | ||
| 0.091 | 0.034 | 0.1 | GABA aminotransferase inhibitor | 0.1 0.027 DBMET00531 | DBMET00531 | |
| 0.093 | 0.037 | 0.093 | Caspase 7 inhibitor | 0.076 0.071 DBMET00531 | ||
| 0.08 | 0.024 | 0.08 | Interferon inducer | 0.067 0.039 DBMET00531 | ||
| 0.109 | 0.053 | 0.115 | Carbonic anhydrase III inhibitor | 0.115 0.048 DBMET00531 | DBMET00531 | |
| 0.067 | 0.013 | 0.067 | Mannosidase inhibitor | 0.066 0.014 DBMET00531 | ||
| 0.06 | 0.007 | 0.067 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.067 0.005 DBMET00531 | DBMET00531 | |
| 0.211 | 0.158 | 0.211 | Transcription factor NF kappa B inhibitor | |||
| 0.059 | 0.007 | 0.067 | Glutamate (mGluR8) agonist | 0.067 0.005 DBMET00531 | DBMET00531 | |
| 0.07 | 0.018 | 0.07 | Ryanodine receptor antagonist | 0.069 0.018 DBMET00531 | ||
| 0.104 | 0.052 | 0.104 | Interleukin 1 beta converting enzyme inhibitor | |||
| 0.076 | 0.025 | 0.076 | Aldose reductase inhibitor | |||
| 0.059 | 0.007 | 0.062 | Kainate receptor agonist | 0.062 0.006 DBMET00531 | DBMET00531 | |
| 0.072 | 0.022 | 0.072 | Autotaxin inhibitor | |||
| 0.087 | 0.037 | 0.087 | Opioid mu receptor antagonist | |||
| 0.125 | 0.075 | 0.129 | Vanilloid 1 agonist | 0.129 0.068 DBMET00531 | DBMET00531 | |
| 0.138 | 0.088 | 0.138 | Phospholipase A2 inhibitor | |||
| 0.17 | 0.122 | 0.17 | Cyclic AMP phosphodiesterase inhibitor | 0.17 0.122 DBMET00531 | ||
| 0.12 | 0.072 | 0.125 | Sphingosine 1-phosphate receptor 4 antagonist | 0.125 0.064 DBMET00531 | DBMET00531 | |
| 0.093 | 0.045 | 0.093 | GABA A receptor agonist | |||
| 0.067 | 0.02 | 0.074 | Dihydroorotate oxidase inhibitor | 0.074 0.014 DBMET00531 | DBMET00531 | |
| 0.12 | 0.074 | 0.12 | Nav1.3 sodium channel blocker | |||
| 0.064 | 0.018 | 0.064 | Immunoglobulin Fc receptor antagonist | 0.064 0.017 DBMET00531 | ||
| 0.081 | 0.035 | 0.081 | Carbonic anhydrase inhibitor | |||
| 0.138 | 0.094 | 0.142 | Hexokinase inhibitor | 0.142 0.088 DBMET00531 | DBMET00531 | |
| 0.058 | 0.014 | 0.058 | Thymidine kinase inhibitor | 0.044 0.024 DBMET00531 | ||
| 0.07 | 0.027 | 0.07 | Calcium channel P-type blocker | 0.068 0.033 DBMET00531 | ||
| 0.079 | 0.036 | 0.079 | Potassium channel (Tandem pore domain) blocker | 0.079 0.037 DBMET00531 | ||
| 0.114 | 0.071 | 0.114 | Transcription factor STAT6 inhibitor | 0.111 0.077 DBMET00531 | ||
| 0.058 | 0.016 | 0.063 | Histamine H2 receptor agonist | 0.063 0.013 DBMET00531 | DBMET00531 | |
| 0.055 | 0.012 | 0.055 | Histamine H1 receptor agonist | 0.054 0.013 DBMET00531 | ||
| 0.058 | 0.015 | 0.058 | Geranyltranstransferase inhibitor | 0.055 0.018 DBMET00531 | ||
| 0.054 | 0.011 | 0.054 | RNA-directed RNA polymerase inhibitor | |||
| 0.056 | 0.014 | 0.056 | Glycine transporter 1 inhibitor | |||
| 0.073 | 0.031 | 0.073 | Carbonic anhydrase IX inhibitor | |||
| 0.074 | 0.033 | 0.074 | 5 Hydroxytryptamine 2A agonist | |||
| 0.061 | 0.02 | 0.061 | Squalene epoxidase inhibitor | 0.056 0.025 DBMET00531 | ||
| 0.055 | 0.013 | 0.055 | Nerve growth factor antagonist | 0.054 0.014 DBMET00531 | ||
| 0.111 | 0.07 | 0.117 | TRPA1 agonist | 0.117 0.062 DBMET00531 | DBMET00531 | |
| 0.084 | 0.044 | 0.096 | Keratolytic | 0.096 0.033 DBMET00531 | DBMET00531 | |
| 0.044 | 0.005 | 0.044 | Purinergic P2Y15 antagonist | 0.044 0.005 DBMET00531 | ||
| 0.096 | 0.057 | 0.096 | Alcohol dehydrogenase inhibitor | 0.096 0.057 DBMET00531 | ||
| 0.083 | 0.045 | 0.083 | Janus tyrosine kinase 2 inhibitor | |||
| 0.084 | 0.046 | 0.084 | Nicotinic alpha4beta2 receptor antagonist | 0.076 0.054 DBMET00531 | ||
| 0.091 | 0.054 | 0.091 | Bromodomain-containing protein 2 inhibitor | 0.089 0.057 DBMET00531 | ||
| 0.051 | 0.015 | 0.051 | GABA uptake inhibitor | 0.05 0.016 DBMET00531 | ||
| 0.063 | 0.028 | 0.063 | Sphingosine kinase 2 inhibitor | 0.058 0.034 DBMET00531 | ||
| 0.073 | 0.038 | 0.073 | 5 Hydroxytryptamine 3A antagonist | |||
| 0.068 | 0.033 | 0.071 | Transcription factor RelA inhibitor | 0.071 0.028 DBMET00531 | DBMET00531 | |
| 0.085 | 0.051 | 0.085 | Opioid kappa receptor antagonist | |||
| 0.049 | 0.014 | 0.049 | Heme oxygenase inhibitor | 0.047 0.018 DBMET00531 | ||
| 0.062 | 0.028 | 0.069 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.069 0.022 DBMET00531 | DBMET00531 | |
| 0.059 | 0.024 | 0.063 | Lysophosphatidic acid 3 receptor antagonist | 0.063 0.019 DBMET00531 | DBMET00531 | |
| 0.07 | 0.036 | 0.074 | Protease 3C (Human rhinovirus) inhibitor | 0.074 0.033 DBMET00531 | DBMET00531 | |
| 0.086 | 0.053 | 0.086 | Histamine H2 receptor antagonist | |||
| 0.057 | 0.024 | 0.057 | HCV NS3/NS4A protease inhibitor | |||
| 0.045 | 0.012 | 0.045 | HCV NS5B polymerase inhibitor | |||
| 0.057 | 0.024 | 0.057 | Adenosine deaminase inhibitor | 0.054 0.026 DBMET00531 | ||
| 0.042 | 0.009 | 0.042 | Nicotinic alpha3beta4 receptor agonist | 0.039 0.011 DBMET00531 | ||
| 0.054 | 0.022 | 0.054 | Thymidylate synthase inhibitor | |||
| 0.129 | 0.097 | 0.129 | Acetylcholine M1 receptor antagonist | |||
| 0.053 | 0.022 | 0.053 | Cytokine production stimulant | 0.051 0.027 DBMET00531 | ||
| 0.122 | 0.091 | 0.128 | Protein kinase stimulant | 0.128 0.085 DBMET00531 | DBMET00531 | |
| 0.042 | 0.011 | 0.043 | Uridine phosphorylase inhibitor | 0.043 0.01 DBMET00531 | DBMET00531 | |
| 0.053 | 0.022 | 0.053 | Oxytocin agonist | 0.052 0.022 DBMET00531 | ||
| 0.103 | 0.072 | 0.103 | Alpha 2b adrenoreceptor antagonist | |||
| 0.106 | 0.076 | 0.106 | 5 Hydroxytryptamine 2B antagonist | |||
| 0.078 | 0.048 | 0.078 | Acetylcholine M4 receptor antagonist | |||
| 0.049 | 0.02 | 0.049 | Dihydrofolate reductase inhibitor | |||
| 0.047 | 0.018 | 0.051 | Membrane dipeptidase inhibitor | 0.051 0.015 DBMET00531 | DBMET00531 | |
| 0.049 | 0.02 | 0.049 | GABA B receptor antagonist | |||
| 0.088 | 0.059 | 0.088 | Opioid antagonist | |||
| 0.202 | 0.174 | 0.202 | Antithrombotic | |||
| 0.087 | 0.059 | 0.096 | Ornithine decarboxylase inhibitor | 0.096 0.048 DBMET00531 | DBMET00531 | |
| 0.064 | 0.036 | 0.066 | Carbonic anhydrase stimulant | 0.066 0.035 DBMET00531 | DBMET00531 | |
| 0.057 | 0.03 | 0.057 | Nicotinic alpha3beta2 receptor antagonist | 0.056 0.032 DBMET00531 | ||
| 0.114 | 0.086 | 0.114 | DNA repair enzyme inhibitor | 0.114 0.085 DBMET00531 | ||
| 0.098 | 0.071 | 0.103 | Expectorant | 0.103 0.065 DBMET00531 | DBMET00531 | |
| 0.14 | 0.113 | 0.14 | Tumour necrosis factor antagonist | |||
| 0.061 | 0.034 | 0.061 | Cathepsin B inhibitor | |||
| 0.033 | 0.007 | 0.035 | Vanilloid 2 agonist | 0.035 0.006 DBMET00531 | DBMET00531 | |
| 0.03 | 0.004 | 0.03 | Antibiotic Anthracycline-like | 0.021 0.01 DBMET00531 | ||
| 0.035 | 0.009 | 0.035 | Estrogen-related receptor gamma antagonist | 0.032 0.013 DBMET00531 | ||
| 0.116 | 0.091 | 0.116 | Calcium channel blocker | |||
| 0.033 | 0.008 | 0.033 | Hedgehog signaling activator | 0.033 0.009 DBMET00531 | ||
| 0.106 | 0.081 | 0.106 | Caspase 3 inhibitor | |||
| 0.098 | 0.073 | 0.098 | Beta glucuronidase inhibitor | |||
| 0.17 | 0.145 | 0.17 | Spasmolytic | |||
| 0.084 | 0.06 | 0.084 | Calcium antagonist | 0.082 0.062 DBMET00531 | ||
| 0.043 | 0.019 | 0.045 | Arginase inhibitor | 0.045 0.018 DBMET00531 | DBMET00531 | |
| 0.045 | 0.021 | 0.045 | Substance P antagonist | |||
| 0.035 | 0.011 | 0.035 | Nicotinic alpha4beta2 receptor agonist | 0.033 0.014 DBMET00531 | ||
| 0.028 | 0.005 | 0.033 | Carbonic anhydrase VIII inhibitor | 0.033 0.004 DBMET00531 | DBMET00531 | |
| 0.028 | 0.005 | 0.033 | Carbonic anhydrase X inhibitor | 0.033 0.004 DBMET00531 | DBMET00531 | |
| 0.042 | 0.019 | 0.042 | Vanilloid 3 antagonist | 0.042 0.018 DBMET00531 | ||
| 0.03 | 0.008 | 0.03 | Complement factor 1s inhibitor | 0.03 0.008 DBMET00531 | ||
| 0.038 | 0.016 | 0.038 | Potassium channel small-conductance Ca-activated activator | 0.034 0.019 DBMET00531 | ||
| 0.102 | 0.081 | 0.102 | Calcium channel (voltage-sensitive) blocker | |||
| 0.032 | 0.01 | 0.032 | Thymidine phosphorylase inhibitor | 0.029 0.014 DBMET00531 | ||
| 0.036 | 0.015 | 0.039 | Glutamate (mGluR3) agonist | 0.039 0.01 DBMET00531 | DBMET00531 | |
| 0.047 | 0.026 | 0.048 | AICAR transformylase inhibitor | 0.048 0.024 DBMET00531 | DBMET00531 | |
| 0.03 | 0.009 | 0.039 | Glutamate (mGluR1a) agonist | 0.039 0.006 DBMET00531 | DBMET00531 | |
| 0.039 | 0.02 | 0.039 | Phosphoglycerate kinase inhibitor | 0.037 0.022 DBMET00531 | ||
| 0.03 | 0.011 | 0.03 | Corticotropin releasing factor 1 receptor antagonist | |||
| 0.052 | 0.033 | 0.055 | Potassium channel (Inward rectifier) activator | 0.055 0.027 DBMET00531 | DBMET00531 | |
| 0.06 | 0.042 | 0.06 | Acetylcholine M5 receptor antagonist | |||
| 0.03 | 0.011 | 0.032 | Lysophosphatidic acid receptor 1 agonist | 0.032 0.009 DBMET00531 | DBMET00531 | |
| 0.03 | 0.012 | 0.034 | Nicotinic acid receptor 2 antagonist | 0.034 0.009 DBMET00531 | DBMET00531 | |
| 0.075 | 0.057 | 0.075 | Estrogen receptor alpha antagonist | |||
| 0.149 | 0.132 | 0.149 | Focal adhesion kinase 2 inhibitor | |||
| 0.049 | 0.032 | 0.052 | Potassium channel (ATP-sensitive) activator | 0.052 0.027 DBMET00531 | DBMET00531 | |
| 0.066 | 0.048 | 0.07 | Sphingosine 1-phosphate receptor 4 agonist | 0.07 0.044 DBMET00531 | DBMET00531 | |
| 0.023 | 0.005 | 0.024 | Telomerase stimulant | 0.024 0.005 DBMET00531 | DBMET00531 | |
| 0.028 | 0.012 | 0.028 | Acid ceramidase inhibitor | 0.028 0.012 DBMET00531 | ||
| 0.055 | 0.038 | 0.056 | Epithelial sodium channel blocker | 0.056 0.035 DBMET00531 | DBMET00531 | |
| 0.1 | 0.083 | 0.1 | Anesthetic local | |||
| 0.022 | 0.006 | 0.022 | Methylmalonyl-CoA mutase inhibitor | 0.022 0.006 DBMET00531 | ||
| 0.143 | 0.127 | 0.145 | I kappa B kinase epsilon inhibitor | 0.145 0.125 DBMET00531 | DBMET00531 | |
| 0.09 | 0.074 | 0.09 | Phosphodiesterase 6D inhibitor | 0.089 0.077 DBMET00531 | ||
| 0.074 | 0.059 | 0.074 | Glutamate receptor agonist | |||
| 0.044 | 0.029 | 0.046 | Glutamate (mGluR4) antagonist | 0.046 0.025 DBMET00531 | DBMET00531 | |
| 0.123 | 0.108 | 0.123 | Heat shock protein 90 antagonist | |||
| 0.028 | 0.014 | 0.028 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.028 0.014 DBMET00531 | ||
| 0.037 | 0.022 | 0.037 | Tryptophan 5 hydroxylase inhibitor | 0.037 0.022 DBMET00531 | ||
| 0.16 | 0.146 | 0.16 | Immunostimulant | |||
| 0.038 | 0.024 | 0.041 | Glutamate (mGluR3) antagonist | 0.041 0.02 DBMET00531 | DBMET00531 | |
| 0.072 | 0.058 | 0.078 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.078 0.053 DBMET00531 | DBMET00531 | |
| 0.058 | 0.044 | 0.058 | Androgen agonist | 0.058 0.044 DBMET00531 | ||
| 0.032 | 0.019 | 0.033 | Epoxide hydrolase 1 inhibitor | 0.033 0.018 DBMET00531 | DBMET00531 | |
| 0.071 | 0.057 | 0.071 | Adenosine A3 receptor antagonist | |||
| 0.048 | 0.036 | 0.048 | Topoisomerase II beta inhibitor | 0.048 0.037 DBMET00531 | ||
| 0.035 | 0.023 | 0.035 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | |||
| 0.023 | 0.01 | 0.023 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.023 0.01 DBMET00531 | ||
| 0.018 | 0.006 | 0.02 | Lysophosphatidic acid receptor 3 agonist | 0.02 0.005 DBMET00531 | DBMET00531 | |
| 0.028 | 0.017 | 0.028 | Glucosylceramidase stimulant | 0.028 0.017 DBMET00531 | ||
| 0.028 | 0.017 | 0.03 | Lysine carboxypeptidase inhibitor | 0.03 0.016 DBMET00531 | DBMET00531 | |
| 0.018 | 0.008 | 0.018 | Purinergic P2Y1 agonist | 0.017 0.008 DBMET00531 | ||
| 0.022 | 0.012 | 0.023 | Neuraminidase (Influenza B) inhibitor | 0.023 0.011 DBMET00531 | DBMET00531 | |
| 0.045 | 0.034 | 0.045 | Glycine transporter 2 inhibitor | |||
| 0.038 | 0.027 | 0.041 | Potassium channel Kv1.1 blocker | 0.041 0.021 DBMET00531 | DBMET00531 | |
| 0.016 | 0.006 | 0.018 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.018 0.005 DBMET00531 | DBMET00531 | |
| 0.045 | 0.035 | 0.045 | Antimetabolite | |||
| 0.077 | 0.067 | 0.077 | Inducible nitric-oxide synthase inhibitor | |||
| 0.035 | 0.024 | 0.035 | Adenosine uptake inhibitor | 0.034 0.026 DBMET00531 | ||
| 0.046 | 0.036 | 0.048 | Aldosterone antagonist | 0.048 0.032 DBMET00531 | DBMET00531 | |
| 0.086 | 0.076 | 0.086 | MAP kinase kinase 1 inhibitor | |||
| 0.043 | 0.033 | 0.044 | Glutamate (mGluR group III) antagonist | 0.044 0.03 DBMET00531 | DBMET00531 | |
| 0.038 | 0.029 | 0.043 | Dihydropteroate synthase inhibitor | 0.043 0.023 DBMET00531 | DBMET00531 | |
| 0.048 | 0.038 | 0.048 | Dopamine D4 agonist | |||
| 0.052 | 0.043 | 0.052 | Glucosylceramidase inhibitor | |||
| 0.035 | 0.026 | 0.035 | Ceramide glucosyltransferase inhibitor | 0.033 0.029 DBMET00531 | ||
| 0.055 | 0.047 | 0.055 | Cyclin-dependent kinase 6 inhibitor | |||
| 0.072 | 0.063 | 0.072 | Macrophage migration inhibitory factor inhibitor | |||
| 0.017 | 0.008 | 0.019 | Thromboxane A2 agonist | 0.019 0.007 DBMET00531 | DBMET00531 | |
| 0.145 | 0.136 | 0.145 | Anticonvulsant | |||
| 0.045 | 0.036 | 0.045 | Glycine transporter inhibitor | |||
| 0.023 | 0.015 | 0.024 | Isoleucine-tRNA ligase inhibitor | 0.024 0.013 DBMET00531 | DBMET00531 | |
| 0.021 | 0.013 | 0.022 | Retinoid X beta receptor antagonist | 0.022 0.011 DBMET00531 | DBMET00531 | |
| 0.036 | 0.028 | 0.036 | Delayed rectifier potassium channel blocker | 0.036 0.028 DBMET00531 | ||
| 0.026 | 0.018 | 0.026 | 5 Hydroxytryptamine 1F agonist | |||
| 0.037 | 0.029 | 0.039 | Retinoid X receptor antagonist | 0.039 0.025 DBMET00531 | DBMET00531 | |
| 0.014 | 0.007 | 0.017 | Glutamate (mGluR6) agonist | 0.017 0.005 DBMET00531 | DBMET00531 | |
| 0.033 | 0.026 | 0.035 | Retinoid X alpha receptor antagonist | 0.035 0.023 DBMET00531 | DBMET00531 | |
| 0.059 | 0.052 | 0.06 | Histone deacetylase SIRT3 inhibitor | 0.06 0.048 DBMET00531 | DBMET00531 | |
| 0.021 | 0.014 | 0.021 | Factor XIII inhibitor | 0.021 0.014 DBMET00531 | ||
| 0.146 | 0.139 | 0.151 | Insulin sensitizer | 0.151 0.132 DBMET00531 | DBMET00531 | |
| 0.037 | 0.031 | 0.037 | 5 Hydroxytryptamine 2B agonist | |||
| 0.028 | 0.022 | 0.028 | MAP3K8 inhibitor | 0.028 0.024 DBMET00531 | ||
| 0.02 | 0.014 | 0.02 | Imidazoline I1 receptor antagonist | 0.019 0.017 DBMET00531 | ||
| 0.014 | 0.008 | 0.016 | Carbonic anhydrase XI inhibitor | 0.016 0.005 DBMET00531 | DBMET00531 | |
| 0.028 | 0.022 | 0.028 | 5 Hydroxytryptamine 6 agonist | |||
| 0.035 | 0.03 | 0.035 | TRPM8 blocker | |||
| 0.021 | 0.016 | 0.021 | Protease (Human cytomegalovirus) inhibitor | 0.021 0.017 DBMET00531 | ||
| 0.087 | 0.082 | 0.091 | Bile acid receptor antagonist | 0.091 0.072 DBMET00531 | DBMET00531 | |
| 0.024 | 0.019 | 0.026 | Glutamate (mGluR1) agonist | 0.026 0.014 DBMET00531 | DBMET00531 | |
| 0.038 | 0.033 | 0.038 | CF transmembrane conductance regulator antagonist | 0.038 0.034 DBMET00531 | ||
| 0.047 | 0.042 | 0.047 | Prolyl endopeptidase inhibitor | 0.046 0.043 DBMET00531 | ||
| 0.012 | 0.008 | 0.012 | Purine nucleoside phosphorylase inhibitor | |||
| 0.016 | 0.012 | 0.016 | Nicotinic alpha4 receptor agonist | |||
| 0.094 | 0.09 | 0.096 | Adenylate cyclase inhibitor | 0.096 0.088 DBMET00531 | DBMET00531 | |
| 0.036 | 0.033 | 0.038 | Toll-Like receptor 2 agonist | 0.038 0.031 DBMET00531 | DBMET00531 | |
| 0.021 | 0.018 | 0.024 | Prostaglandin F2 alpha agonist | 0.024 0.014 DBMET00531 | DBMET00531 | |
| 0.055 | 0.052 | 0.055 | Cyclin D1 inhibitor | 0.055 0.051 DBMET00531 | ||
| 0.013 | 0.01 | 0.013 | Cyclin D2 inhibitor | 0.013 0.01 DBMET00531 | ||
| 0.054 | 0.051 | 0.054 | Sphingosine kinase inhibitor | |||
| 0.053 | 0.05 | 0.055 | Leukotriene C antagonist | 0.055 0.045 DBMET00531 | DBMET00531 | |
| 0.052 | 0.049 | 0.052 | 5 Hydroxytryptamine 7 agonist | |||
| 0.031 | 0.028 | 0.033 | Protein kinase (CK2) beta inhibitor | 0.033 0.024 DBMET00531 | DBMET00531 | |
| 0.087 | 0.084 | 0.087 | Nitric-oxide synthase inhibitor | |||
| 0.034 | 0.031 | 0.034 | Diamine oxidase inhibitor | 0.034 0.031 DBMET00531 | ||
| 0.017 | 0.014 | 0.017 | Cyclin T1 inhibitor | 0.016 0.015 DBMET00531 | ||
| 0.084 | 0.082 | 0.084 | Alpha 2c adrenoreceptor antagonist | |||
| 0.031 | 0.029 | 0.034 | Retinoid X alpha receptor agonist | 0.034 0.025 DBMET00531 | DBMET00531 | |
| 0.007 | 0.005 | 0.008 | DNA topoisomerase III inhibitor | 0.008 0.004 DBMET00531 | DBMET00531 | |
| 0.124 | 0.122 | 0.125 | MAP kinase 3 inhibitor | 0.125 0.121 DBMET00531 | DBMET00531 | |
| 0.016 | 0.014 | 0.019 | Nicotinic acid receptor 1 antagonist | 0.019 0.01 DBMET00531 | DBMET00531 | |
| 0.045 | 0.043 | 0.045 | Bombesin 2 receptor antagonist | |||
| 0.016 | 0.014 | 0.016 | Alpha 2a adrenoreceptor agonist | |||
| 0.031 | 0.03 | 0.033 | Melatonin receptor 1A agonist | 0.033 0.024 DBMET00531 | DBMET00531 | |
| 0.042 | 0.041 | 0.042 | CC chemokine 4 receptor antagonist | |||
| 0.042 | 0.041 | 0.042 | Purinergic P2X4 antagonist | 0.042 0.041 DBMET00531 | ||
| 0.009 | 0.008 | 0.009 | Corticotropin releasing factor antagonist | |||
| 0.027 | 0.027 | 0.028 | Lysophosphatidic acid 2 receptor antagonist | 0.028 0.026 DBMET00531 | DBMET00531 | |
| 0.029 | 0.028 | 0.029 | Calcitonin receptor agonist | 0.029 0.028 DBMET00531 | ||
| 0.03 | 0.03 | 0.031 | Free fatty acid receptor 1 antagonist | 0.031 0.027 DBMET00531 | DBMET00531 | |
| 0.024 | 0.025 | 0.025 | Integrin alpha2beta1 antagonist | 0.025 0.022 DBMET00531 | DBMET00531 | |
| 0.073 | 0.075 | 0.078 | Glutathione S-transferase inhibitor | 0.078 0.065 DBMET00531 | DBMET00531 | |
| 0.048 | 0.051 | 0.05 | Heparanase inhibitor | 0.05 0.045 DBMET00531 | DBMET00531 | |
| 0.027 | 0.031 | 0.029 | ATP citrate lysase inhibitor | 0.029 0.026 DBMET00531 | DBMET00531 | |
| 0.032 | 0.036 | 0.034 | Integrin alpha2 antagonist | 0.034 0.031 DBMET00531 | DBMET00531 | |
| 0.056 | 0.063 | 0.059 | Aryl hydrocarbon receptor antagonist | 0.059 0.056 DBMET00531 | DBMET00531 | |
| 0.036 | 0.048 | 0.042 | Dihydroorotase inhibitor | 0.042 0.035 DBMET00531 | DBMET00531 | |
| 0.019 | 0.056 | 0.139 | 5-Alpha-reductase inhibitor | 0.139 0.007 DBMET00531 | DBMET00531 | |
| 0.072 | 0.118 | 0.253 | Xanthine oxidase inhibitor | 0.253 0.012 DBMET00531 | DBMET00531 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |